Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

News Focus

Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)

Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by SizzlinSteakson May 18, 2018 7:34am

118 Views

Post# 28051010

RE:TLT.v what is the modified treatment procedure?

The recurrence on patients 1 to 4 was in the upper urinary tract because they did not treat that area of the bladder. Modifications were made to treat the upper urinary tract so it stands to reason that this area would now be cancer free. Simple logic. If you are asking about the specifics regarding how it was treated....we do not have that information. It remains with the oncologists.

Mickey2 wrote:

From May 1 NR, regarding Patient #5 and 6

" The last two patients, who received the Therapeutic Dose with a modified treatment procedure, are considered clinically cancer free, as of last clinical assessment."

Anyone know what was modified compared to patient #4

From May 1 NR, regarding Patient #5 and 6

" The last two patients, who received the Therapeutic Dose with a modified treatment procedure, are considered clinically cancer free, as of last clinical assessment."